Invicro and iThera Medical Announce a Strategic Partnership to Enhance in vivo Imaging Capabilities with the MSOT inVision Optoacoustic Imaging Platform
Invicro LLC, a Konica Minolta company and iTheraMedical GmbH announced a unique partnership with the placement of the MSOT inVision platform in Invicro’s in vivo laboratory out of its Boston headquarters. Both companies will come together to uniquely offer Pharmaceutical, Biotech and Academia sponsors services from the optoacoustic platform that will identify and quantify disease-related biomarkers at both a molecular and anatomical level through pre-clinical full body tomographic scans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190430005605/en/
Mr. Tullio Giannitti, General Manager, Americas at iThera Medical and Ms. Ciara Finucane, Senior Director and Business Leader of Discovery Research at Invicro with the MSOT inVision platform. (Photo: Business Wire)
Invicro is a leading provider of quantitative imaging biomarkers, core lab services and software solutions for research and drug development, and Munich-based iThera Medical develops unique multispectral optoacoustic imaging technologies enabling non-invasive, real-time visualization of anatomical, functional and molecular information in living tissue at high spatial resolution. This collaboration will deliver more versatile and accurate imaging biomarkers for preclinical drug discovery research, while reducing the duration and costs of biopharmaceutical drug development.
“We are pleased to partner with iThera Medical to jointly offer enhanced pre-clinical imaging capabilities with the MSOT inVision platform,” said Ms. Ciara Finucane, MSc, Senior Director and Business Leader of Discovery Research at Invicro. “Combining iThera Medical’s technology with Invicro’s advanced quantitative imaging biomarkers offers our Pharma and Biotech sponsors a comprehensive and efficient solution to answer their research questions faster.”
“With this partnership, iThera Medical and Invicro continue to strengthen their strategy jointly to offer global pharma, biotech, and academic research communities the industry’s most premium imaging, analytics and technology solutions to support the complete drug discovery value chain,” stated Mr. Tullio Giannitti, General Manager, Americas at iThera Medical. “This collaboration is further proof of the value that MSOT imaging brings to clients in drug discovery. Invicro’s strategic imaging services align with iThera Medical’s vision, technologies and industry experience. We are pleased to have the opportunity to collaborate with the global leader in imaging biomarker services.”
iThera Medical GmbH develops and markets a novel in-vivo biomedical imaging technology, “MSOT” = multispectral optoacoustic tomography. MSOT utilizes the photoacoustic effect to visualize and quantify anatomical, functional and molecular information in living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardio-vascular problems). In the future, MSOT also promises to become a valuable tool in clinical diagnostics. iThera Medical is headquartered in Munich, Germany with a US subsidiary in Boston.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
VP, Global Marketing
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Assimoco Group Selects Moody’s Analytics SolvencyWatch ™ Solution29.5.2020 11:00:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, today announced that its software has been selected by Assimoco Group, an Italian insurance group and the insurance provider for the Italian Cooperative Movement since 1978. Assimoco Group will use the Moody’s Analytics SolvencyWatch solution to monitor key solvency metrics. Powered by Moody’s Analytics award-winning modeling capabilities, the SolvencyWatch solution quickly calculates an insurer’s assets and liabilities to reflect the latest market conditions, enabling chief risk officers (CROs) to monitor their solvency position in real time. The tool’s intuitive dashboard allows CROs and risk teams to visualize the impact on crucial solvency metrics under changes to market and non-market risks, and communicate to stakeholders what is driving changes in those metrics. “The Moody’s Analytics SolvencyWatch solution will allow us to monitor our solvency position frequently, accurately, and cost effectively,” said Ruggero Fre
Wipro Appoints Thierry Delaporte as CEO & Managing Director29.5.2020 07:21:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the appointment of Thierry Delaporte as the Chief Executive Officer and Managing Director of the company, effective July 6, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005916/en/ Thierry Delaporte (Photo: Business Wire) Until recently, Thierry Delaporte was the Chief Operating Officer of Capgemini Group and a member of its Group Executive Board. During his twenty-five year career with Capgemini, he held several leadership roles including that of Chief Executive Officer of the Global Financial Services Strategic Business Unit, and head of all global service lines. He also oversaw Capgemini’s India operations, and led the group’s transformation agenda, conceptualizing and driving several strategic programs across various business units. “I am delighted to
Ipsen Appoints David Loew as Chief Executive Officer29.5.2020 07:05:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005876/en/ David Loew, CEO at Ipsen as of July 1st 2020 (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Directors has appointed David Loew as its new Chief Executive Officer (CEO) and as Board member. The CEO appointment will take effect on July 1st, 2020. The Board of Directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1st, 2020 and will continue in his role of Chief Financial Officer. David Loew will be based at Ipsen’s headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen’s continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient-cent
New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CEST | Press release
Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a
European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CEST | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit